Nascent Biotech, Inc. (NBIO)
| Previous Close | 0.0550 |
| Open | 0.0500 |
| Bid | 0.0500 x 0 |
| Ask | 0.0520 x 0 |
| Day's Range | 0.0500 - 0.0520 |
| 52 Week Range | 0.0500 - 0.2800 |
| Volume | |
| Avg. Volume | 71,329 |
| Market Cap | 8.61M |
| Beta (5Y Monthly) | -3.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Aug 16, 2024 - Aug 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswirePresenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie
ACCESSWIRENascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces ...
- ACCESSWIRE
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray ...
